Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3

Acute myeloid leukemia (AML) patients with FLT3/ITD mutations have a poor prognosis. Monotherapy with selective FLT3 tyrosine kinase inhibitors (TKIs) have shown transient and limited efficacy due to the development of resistance. Arsenic trioxide (ATO, As(2)O(3)) has been proven effective in treati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Nagai, Kozo, Hou, Lihong, Li, Li, Nguyen, Bao, Seale, Tessa, Shirley, Courtney, Ma, Hayley, Levis, Mark, Ghiaur, Gabriel, Duffield, Amy, Small, Donald
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Priority Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152471/
https://ncbi.nlm.nih.gov/pubmed/30250637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25972
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak